Market Cap 198.06M
Revenue (ttm) 287.00M
Net Income (ttm) -317.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -110.45%
Debt to Equity Ratio 0.00
Volume 529,500
Avg Vol 268,580
Day's Range N/A - N/A
Shares Out 26.29M
Stochastic %K 7%
Beta 2.02
Analysts Hold
Price Target $5.90

Latest News on LOGC

ContextLogic Inc. Reports Third-Quarter 2024 Financial Results

Nov 7, 2024, 4:10 PM EST - 4 months ago

ContextLogic Inc. Reports Third-Quarter 2024 Financial Results


ContextLogic Inc. Reports Second-Quarter Financial Results

Aug 8, 2024, 4:15 PM EDT - 7 months ago

ContextLogic Inc. Reports Second-Quarter Financial Results


AstraZeneca pays 660% premium for gene therapy firm LogicBio

Oct 3, 2022, 8:25 AM EDT - 2 years ago

AstraZeneca pays 660% premium for gene therapy firm LogicBio

AZN


Why LogicBio Therapeutics Shares Are Popping Off Today

May 9, 2022, 10:26 AM EDT - 3 years ago

Why LogicBio Therapeutics Shares Are Popping Off Today


LogicBio Therapeutics Provides Business Updates

Dec 22, 2021, 8:00 AM EST - 3 years ago

LogicBio Therapeutics Provides Business Updates


LogicBio Therapeutics Announces Clinical and Corporate Updates

Apr 27, 2021, 7:00 AM EDT - 4 years ago

LogicBio Therapeutics Announces Clinical and Corporate Updates


Looking In On LogicBio

Nov 17, 2020, 12:04 AM EST - 4 years ago

Looking In On LogicBio